NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial
Status:
Recruiting
Trial end date:
2026-06-30
Target enrollment:
Participant gender:
Summary
To learn if the proposed dose of 177Lu rhPSMA-10.1 is safe. Phase 2 will open if the Phase 1
dose is found to be safe.
To learn about the safety and effects of 177Lu rhPSMA-10.1 alone and with androgen
deprivation therapy (ADT) on patients with high-risk, localized prostate cancer before they
have surgery to remove the disease.